Intact parathyroid hormone levels in renal transplant patients with normal transplant function

Clinical Transplantation

Volumn 25, Issue 5, 2011, Pages

  Bleskestad, Inger H ^a   Bergrem, Harald ^a,b   Leivestad, Torbjørn ^c   Gøransson, Lasse G ^a,b  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chronic kidney disease; Intact parathyroid hormone; Mineral and bone disorder; Renal transplantation; Secondary hyperparathyroidism

Indexed keywords

PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTICLE; FEMALE; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HORMONE DETERMINATION; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHOSPHATE BLOOD LEVEL; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY;

FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PARATHYROID HORMONE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 80054121213     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01515.x     Document Type: Article

References (25)

1. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994: 23: 229.
2. Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998: 13: 436.
3. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003: 42(4 Suppl 3): S1.
4. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009: 113: S1.
5. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999: 130: 461.
6. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004: 19: 1281.
7. Saha HH, Salmela KT, Ahonen PJ et al. Sequential changes in vitamin D and calcium metabolism after successful renal transplantation. Scand J Urol Nephrol 1994: 28: 21.
8. Goransson LG, Bergrem H. Renal transplant and secondary hyperparathyroidism. Scand J Urol Nephrol 2007: 41: 553.
9. Botha JF, Botha JR. Parathyroid function after successful renal transplantation. S Afr J Surg 1997: 35: 113.
10. Asderakis A, Augustine T, Dyer P et al. Pre-emptive kidney transplantation: the attractive alternative. Nephrol Dial Transplant 1998: 13: 1799.
11. Meier-Kriesche HU, Port FK, Ojo AO et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000: 58: 1311.
12. Stavroulopoulos A, Cassidy MJ, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant recipients. Am J Transplant 2007: 7: 2546.
13. Boudville NC, Hodsman AB. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant 2006: 21: 2621.
14. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003: 42: 1050.
15. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005: 80: 1270.
16. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998: 31: 607.
17. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004: 15: 2208.
18. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008: 52: 519.
19. Lewin E, Olgaard K. Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation. Nephrol Dial Transplant 2006: 21: 1766.
20. Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant 2007: 22: 1730.
21. Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005: 20: 1311.
22. Serra AL, Schwarz AA, Wick FH, Marti HP, Wuthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005: 20: 1315.
23. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007: 22: 577.
24. Lopez V, Toledo R, Sola E et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc 2009: 41: 2394.
25. Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007: 2: 898.